Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGE

AGE - AgeX Therapeutics Inc Stock Price, Fair Value and News

0.37USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.370.00
Market Closed
0.00%

AGE Stock Price

View Fullscreen

AGE RSI Chart

AGE Valuation

Market Cap

14.4M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

411.14

EV/EBITDA

-4.21

Price/Free Cashflow

-2.04

AGE Price/Sales (Trailing)

AGE Profitability

Operating Margin

-11.11%

EBT Margin

-27841.67%

Return on Equity

-14.05%

Return on Assets

-115.07%

Free Cashflow Yield

-49.02%

AGE Fundamentals

AGE Revenue

Revenue (TTM)

36.0K

Rev. Growth (Yr)

644.44%

Rev. Growth (Qtr)

76.32%

AGE Earnings

Earnings (TTM)

-14.1M

Earnings Growth (Yr)

-121.81%

Earnings Growth (Qtr)

-102.36%

Breaking Down AGE Revenue

Last 30 days

-4.9%

Last 90 days

-9.3%

Trailing 12 Months

-37.4%

How does AGE drawdown profile look like?

AGE Financial Health

Current Ratio

0.36

AGE Investor Care

Shares Dilution (1Y)

0.01%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202339.0K36.0K00
2022116.5K89.0K61.5K34.0K
2021306.8K252.5K198.3K144.0K
20201.9M1.5M940.5K361.0K
20191.5M1.5M1.5M1.7M
20181.4M1.4M1.4M1.4M
20170001.4M

Tracking the Latest Insider Buys and Sells of AgeX Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 14, 2023
juvenescence ltd
gifted
-
-
-16,447,500
-
Mar 11, 2023
west michael d
sold (taxes)
-625
0.59
-1,060
chief executive officer
Mar 11, 2023
west michael d
acquired
-
-
3,125
chief executive officer
Dec 11, 2022
west michael d
sold (taxes)
-637
0.59
-1,081
chief executive officer
Dec 11, 2022
west michael d
acquired
-
-
3,125
chief executive officer
Sep 11, 2022
west michael d
sold (taxes)
-607
0.5623
-1,081
chief executive officer
Sep 11, 2022
west michael d
acquired
-
-
3,125
chief executive officer
Jun 11, 2022
west michael d
sold (taxes)
-832
0.7702
-1,081
chief executive officer
Jun 11, 2022
west michael d
acquired
-
-
3,125
chief executive officer
Mar 11, 2022
west michael d
sold (taxes)
-886
0.6923
-1,281
chief executive officer

1–10 of 28

Which funds bought or sold AGE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
4,444
4,444
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
-22.00
28.00
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
8,257
8,257
-%
Feb 14, 2024
VANGUARD GROUP INC
added
0.48
-204,745
270,176
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-42,708
55,736
-%
Feb 14, 2024
BROADWOOD CAPITAL INC
unchanged
-
-884,161
1,153,900
0.10%
Feb 14, 2024
LPL Financial LLC
unchanged
-
-3,626
4,733
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
2.36
-6,941
9,567
-%

1–10 of 40

Are Funds Buying or Selling AGE?

Are funds buying AGE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGE
No. of Funds

Unveiling AgeX Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
juvenescence ltd
81.0%
91,473,463
SC 13D/A
Feb 05, 2024
juvenescence ltd
80.6%
89,308,271
SC 13D/A
Jan 17, 2024
juvenescence ltd
80.4%
88,488,113
SC 13D/A
Jan 09, 2024
juvenescence ltd
80.2%
86,925,820
SC 13D/A
Dec 13, 2023
juvenescence ltd
80.4%
88,312,009
SC 13D/A
Nov 16, 2023
juvenescence ltd
79.4%
82,705,949
SC 13D/A
Nov 01, 2023
juvenescence ltd
79.2%
81,995,827
SC 13D/A
Aug 24, 2023
juvenescence ltd
78.6%
79,180,922
SC 13D/A
Apr 12, 2023
juvenescence ltd
78.8%
79,698,968
SC 13D/A
Mar 22, 2023
juvenescence ltd
78.7%
79,425,155
SC 13D/A

Recent SEC filings of AgeX Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
424B3
Prospectus Filed
Feb 14, 2024
8-K
Current Report
Feb 14, 2024
SC 13D/A
13D - Major Acquisition
Feb 13, 2024
EFFECT
EFFECT
Feb 07, 2024
S-4/A
Mergers and Acquisition
Feb 06, 2024
8-K
Current Report
Feb 05, 2024
SC 13D/A
13D - Major Acquisition
Jan 19, 2024
8-K
Current Report
Jan 18, 2024
3
Insider Trading
Jan 17, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to AgeX Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AgeX Therapeutics Inc News

Latest updates
Benzinga3 months ago
Proactive Investors UK5 months ago
Longevity.Technology18 months ago

AgeX Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue76.3%67,00038,0009,00010,0008,0009,00012,0005,00017,75030,50043,25056,00052,33348,66745,000515,000549,000411,000380,000388,000313,000
Cost Of Revenue-33,000-5,0001,0001,0005,0006,0001,0001,0002,00013,0003,0005,00017,0003,0001,00079,00049,00053,00063,000180,000
Gross Profit-34,000-4,0009,0007,0004,0006,0004,00026,00022,00024,00053,000153,00052,00042,00088,000470,000362,000327,000325,000133,000
Operating Expenses-2,390,000-1,890,0002,167,0001,789,0001,554,0001,597,0002,056,0001,893,0001,696,0002,229,0002,346,0002,480,0002,449,0002,410,0003,096,0006,633,0003,641,0003,769,000-3,447,000-9,691,000
  S&GA Expenses-2,172,000-1,730,0001,993,0001,581,0001,392,0001,338,0001,660,0001,517,0001,421,0001,748,0002,022,0001,575,0001,796,0001,475,0001,875,0001,717,0002,194,0002,119,0002,109,0001,968,000
  R&D Expenses-218,000-160,000174,000208,000162,000259,000396,000376,000275,000481,000324,000905,000653,000935,0001,221,0001,469,0001,447,0001,650,0001,338,0001,523,000
EBITDA Margin38.2%-94.94-153-153-140-176-108-76.73-65.26-47.84-44.64-37.30-30.56-28.85--------
Interest Expenses-3,036,000-792,0001,100,000978,000923,000863,000571,000295,000285,000-----------
Income Taxes-----------------18,00054,0003,00073,000-
Earnings Before Taxes-------2,436,000-2,618,000-2,707,000-2,262,000-1,955,000-2,475,000-1,993,000-3,137,000-2,524,000-2,432,000-3,033,000-2,723,000-3,223,000-3,152,000-3,138,000-3,274,000
EBT Margin0%-278-278-278-257-294-162-107-80.68-60.31-48.22-40.11-32.88-30.82--------
Net Income-Infinity%-5,401,000--2,669,000-3,277,000-2,703,000-2,435,000-2,618,000-2,706,000-2,158,000-1,955,000-2,474,000-2,088,000-2,446,000-2,543,000-2,689,000-3,187,000-2,711,000-3,221,000-3,089,000-3,133,000-3,186,000
Net Income Margin-26.8%-390-307-307-282-307-161-106-79.77-60.24-45.21-37.83-31.84-30.10--------
Free Cashflow-Infinity%-1,864,000--2,019,000-1,865,000-1,321,000-1,236,000-1,746,000-1,636,000-1,647,000-1,884,000-1,694,000-2,630,000-1,620,000-1,901,000-------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.5%12,21012,27712,5313,2412,0082,5792,7163,1542,4272,5413,1603,9254,2034,7575,0927,4428,18310,25712,32110,67110,411
  Current Assets-15.5%1,1411,3501,7472,4531,1871,7251,8292,2341,4751,5562,1422,2831,9292,1042,0724,0544,6906,6809,6487,853-
    Cash Equivalents52.1%3972612806454667024485847316158095271,1071,0334682,3523,7685,8138,5866,707-
  Net PPE-------------4426818981,1261,01095184.0090.00-
Liabilities-88.7%3,89734,57332,53620,55617,15715,84114,30715,02912,40510,8359,2639,3217,9496,8795,4674,8253,2402,8502,2942,4402,158
  Current Liabilities-86.9%3,20424,50522,52510,0788,8099,08510,0998,9676,5985,2713,9295,3574,8544,7135,4673,2972,9072,629-2,440-
Shareholder's Equity0.0%100,01799,97799,58998,99498,39997,85096,90393,91293,65093,37993,09591,81090,88089,55588,6082,6174,9437,40710,0278,23110,737
  Retained Earnings-4.4%-127,557-122,200-119,500-116,210-113,500-111,072-108,454-105,748-103,590-101,600-99,161-97,073-94,627-92,084-89,395-86,208-83,497-80,276-77,187-74,054-
  Additional Paid-In Capital0.0%100,01799,97799,58998,99498,39997,85096,90393,91293,65093,37993,09591,81090,88089,55588,60888,35387,75886,97586,48081,499-
Shares Outstanding0.0%37,95137,95137,95137,94937,94737,94337,94237,94137,86837,93737,93537,69137,679--------
Minority Interest9.9%-109-121-111-103-45.00-44.00-44.00-43.00-42.00-42.00-41.00-280-95.00322364399604660706784-
Float------12,100---32,500---19,600---56,400---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations7.7%-1,864-2,019-1,865-1,321-1,236-1,746-1,636-1,647-1,884-1,694-2,630-1,620-1,889-2,244-2,064-2,411-2,372-2,759-2,618-2,046-1,783
  Share Based Compensation14.3%40.0035.0070.00114209198239263272286178178227252252420491515481748210
Cashflow From Investing----10,000-------666--12.00-4.00-4.00-295-15794.00-3.003.00-1,078
Cashflow From Financing0%2,0002,00011,5001,5001,0002,0001,5001,5002,0001,5002,2469921,9772,8071851,287487-9.004,500-263

AGE Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
REVENUES    
Total revenues$ 67$ 9$ 86$ 26
Cost of sales(33)(5)(39)(12)
Gross profit3444714
OPERATING EXPENSES    
Research and development218162552817
General and administrative2,1721,3925,8954,390
Total operating expenses2,3901,5546,4475,207
Loss from operations(2,356)(1,550)(6,400)(5,193)
OTHER EXPENSE, NET:    
Interest expense, net(3,036)(923)(4,928)(2,357)
Change in fair value of warrants35(35)(220)
Other income, net32109
Total other expense, net(3,033)(886)(4,953)(2,568)
NET LOSS(5,389)(2,436)(11,353)(7,761)
Net (income) loss attributable to noncontrolling interest(12)162
NET LOSS ATTRIBUTABLE TO AGEX$ (5,401)$ (2,435)$ (11,347)$ (7,759)
NET LOSS PER COMMON SHARE:    
BASIC$ (0.14)$ (0.06)$ (0.30)$ (0.20)
DILUTED$ (0.14)$ (0.06)$ (0.30)$ (0.20)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:    
BASIC37,95137,94637,95137,944
DILUTED37,95137,94637,95137,944
Grant Revenues [Member]    
REVENUES    
Total revenues$ 21$ 21
Other Revenues [Member]    
REVENUES    
Total revenues$ 46$ 9$ 65$ 26

AGE Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 397$ 645
Accounts and grants receivable, net674
Related party receivables, net4 
Prepaid expenses and other current assets6731,804
Total current assets1,1412,453
Restricted cash5050
Intangible assets, net640738
Convertible note receivable10,379
TOTAL ASSETS12,2103,241
Current liabilities:  
Accounts payable and accrued liabilities1,6711,034
Loans due to Juvenescence, net of debt issuance costs, current portion1,5267,646
Warrant liability180
Insurance premium liability and other current liabilities71,077
Total current liabilities3,20410,078
Loans due to Juvenescence, net of debt issuance costs, net of current portion69310,478
TOTAL LIABILITIES3,89720,556
Commitments and contingencies (Note 11)
Temporary equity preferred stock 
Stockholders’ deficit:  
Preferred stock, $0.0001 par value, 5,000 shares authorized
Common stock, $0.0001 par value, 200,000 shares authorized; and 37,951 and 37,949 shares issued and outstanding, respectively44
Additional paid-in capital100,01798,994
Accumulated deficit(127,557)(116,210)
Total AgeX Therapeutics, Inc. stockholders’ deficit(27,536)(17,212)
Noncontrolling interest(109)(103)
Total stockholders’ deficit(27,645)(17,315)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT12,2103,241
Series A Preferred Stock [Member]  
Current liabilities:  
Temporary equity preferred stock21,135
Series B Preferred Stock [Member]  
Current liabilities:  
Temporary equity preferred stock14,823
Related Party [Member]  
Current assets:  
Related party receivables, net4
Current liabilities:  
Related party payables, net$ 141
AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
 CEO
 WEBSITEwww.agexinc.com
 EMPLOYEES5

AgeX Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for AgeX Therapeutics Inc? What does AGE stand for in stocks?

AGE is the stock ticker symbol of AgeX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AgeX Therapeutics Inc (AGE)?

As of Thu Feb 22 2024, market cap of AgeX Therapeutics Inc is 14.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers. The fair value of AgeX Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AgeX Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AgeX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGE is over valued or under valued. Whether AgeX Therapeutics Inc is cheap or expensive depends on the assumptions which impact AgeX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGE.

What is AgeX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AGE's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 411.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGE PE ratio will change depending on the future growth rate expectations of investors.